Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Depreciation & Amortization (CF) (2016 - 2021)

Historic Depreciation & Amortization (CF) for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q1 2021 value amounting to $201000.0.

  • Rhythm Pharmaceuticals' Depreciation & Amortization (CF) rose 2035.93% to $201000.0 in Q1 2021 from the same period last year, while for Dec 2021 it was $201000.0, marking a year-over-year change of. This contributed to the annual value of $690000.0 for FY2020, which is 1726.62% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Depreciation & Amortization (CF) of $201000.0 as of Q1 2021, which was up 2035.93% from $172000.0 recorded in Q3 2020.
  • In the past 5 years, Rhythm Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $245000.0 in Q1 2019 and a low of $54000.0 during Q1 2017
  • In the last 5 years, Rhythm Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $169500.0 in 2020 and averaged $138250.0.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Depreciation & Amortization (CF) skyrocketed by 30163.93% in 2019, and later tumbled by 3183.67% in 2020.
  • Over the past 5 years, Rhythm Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $60000.0 in 2017, then skyrocketed by 256.67% to $214000.0 in 2018, then decreased by 10.75% to $191000.0 in 2019, then fell by 9.95% to $172000.0 in 2020, then increased by 16.86% to $201000.0 in 2021.
  • Its last three reported values are $201000.0 in Q1 2021, $172000.0 for Q3 2020, and $173000.0 during Q2 2020.